Wells Fargo & Company Trevi Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 23,478 shares of TRVI stock, worth $72,781. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,478
Previous 16,839
39.43%
Holding current value
$72,781
Previous $58,000
18.97%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding TRVI
# of Institutions
74Shares Held
54.3MCall Options Held
15.6KPut Options Held
0-
Nea Management Company, LLC Timonium, MD11.4MShares$35.2 Million3.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$22.9 Million1.3% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$15.6 Million0.44% of portfolio
-
Viking Global Investors LP4.4MShares$13.6 Million0.05% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$10.6 Million1.12% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $181M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...